Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 9.35
- Piotroski Score 1.00
- Grade Outperform
- Symbol (CYT)
- Company Cyteir Therapeutics, Inc.
- Price $3.02
- Changes Percentage (-2.27%)
- Change -$0.07
- Day Low $3.00
- Day High $3.09
- Year High $3.19
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
- Last Earnings 10/16/2015
- Ex-Dividend for 5/16 Dividend 11/06/2015
- Dividend Payable 11/25/2015
- Today N/A
- Next Earnings (Estimated) N/A
- Fiscal Year End N/A
- Average Stock Price Target $2.00
- High Stock Price Target $2.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.93
- Trailing P/E Ratio -3.247311827957
- Forward P/E Ratio -3.247311827957
- P/E Growth -3.247311827957
- Net Income $-43,952,000
Income Statement
Quarterly
Annual
Latest News of CYT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Should You Consider Investing in Vaxcyte (PCVX)?
Baron Funds released their Q3 2024 investor letter for the Baron Health Care Fund, reporting a 5.81% appreciation in the quarter. Vaxcyte, Inc. was highlighted as a top pick, with a one-month return o...
By Yahoo! Finance | 4 days ago -
Incyte Shows Rising Relative Price Performance; Still Shy Of Key Threshold
Learn how to scale out of losing stocks by using three signals, including the Relative Strength (RS) Rating from Investor's Business Daily. Top-performing stocks typically have an RS Rating above 80 i...
By Investor's Business Daily | 1 month ago -
Is Cytokinetics Inc. (CYTK) Positioned for Success with Its Innovative Muscle Modulators?
A recent article highlights Cytokinetics Inc. as a promising small-cap stock for investment. It discusses the impact of interest rate cuts on small and mid-cap stocks and provides insights from expert...
By Yahoo! Finance | 1 month ago
